BLRX

BioLineRx Ltd.

2.72 USD

Last updated Sep 14, 05:28 UTC

Yesterday HIGH

$2.62

Yesterday LOW

$2.51

52w HIGH

$4.56

52w LOW

$2.16

EPS

0.00

PE

0.00

Next Earnings

Nov 23, 2026

Overview News Government Trades Fundamentals

BioLineRx Ltd. stock is down -1.45% since 30 days ago. The next earnings date is Nov 23, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 15 September’s closed higher than August.

Benzinga Newsdesk

Wed Jul 8, 2026

BioLineRx And Hemispherian Announce New Preclinical Data Showing Strong Synergy Between GLIX1 And PARP Inhibitors In Patient-Derived Xenograft Model Of Ovarian Cancer

Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug individually at its optimal
Benzinga Insights

Thu Jun 4, 2026

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights

Wed May 27, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Newsdesk

Wed May 27, 2026

BioLine Rx Q1 Sales $477.000K Beat $343.000K Estimate

BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $477.000 thousand which beat the analyst consensus estimate of $343.000 thousand by 39.07 percent. This is a 87.06 percent increase over sales of $255.000 thousand
Benzinga Newsdesk

Fri May 22, 2026

BioLineRx And Hemispherian Announce Two Abstracts Featuring GLIX1 Will Be Published At ASCO 2026 Annual Meeting

BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing
Vandana Singh

Tue May 19, 2026

BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models

BioLineRx shares new GLIX1 glioblastoma data showing anti-tumor activity, including in temozolomide-resistant cancer models.
Benzinga Newsdesk

Tue May 19, 2026

BioLineRx Announces New Preclinical Data That Further Support The Recently Initiated Phase 1/2a Clinical Trial Evaluating GLIX1 For Recurrent And Progressive GBM And Other High-Grade Gliomas

GBM remains one of the most aggressive and treatment-resistant cancers, urgently in need of breakthrough innovations and more effective treatment.In a comprehensive pre-clinical program, orally administered GLIX1
Benzinga Insights

Mon May 18, 2026

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Newsdesk

Tue Apr 28, 2026

BioLineRx shares are trading higher after the company announces that the first patient has been dosed in its Phase 1/2A study of GLIX-1 for glioblastoma and other high-grade gliomas.
Benzinga Newsdesk

Tue Apr 28, 2026

BioLineRx Announces That The First Patient Has Been Dosed In Its Phase 1/2A Study Of GLIX-1 For The Treatment Of Recurrent And Progressive Glioblastoma And Other High-Grade Gliomas

The GLIX1 program is being conducted under a collaboration between BioLineRx and Hemispherian announced in September 2025. The patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief

USAR $15.56 USD

ORCL $147.76 USD

DIA $525.80 USD

DDOG $221.22 USD

SPY $764.30 USD

NASA NASA $23.37 USD

USO $154.92 USD

GDXU $149.02 USD

BWET BWET $729.28 USD